Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Share-based Compensation: 2015-2025

Historic Share-based Compensation for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $9.6 million.

  • Spyre Therapeutics' Share-based Compensation fell 26.98% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 30.03%. This contributed to the annual value of $44.8 million for FY2024, which is 74.62% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Share-based Compensation of $9.6 million as of Q3 2025, which was up 2.00% from $9.4 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Share-based Compensation high stood at $17.3 million for Q4 2023, and its period low was $1.4 million during Q4 2022.
  • Over the past 3 years, Spyre Therapeutics' median Share-based Compensation value was $9.2 million (recorded in 2024), while the average stood at $8.9 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Share-based Compensation surged by 1,110.23% in 2023, and later slumped by 46.64% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Share-based Compensation (Quarterly) stood at $2.1 million in 2021, then slumped by 31.85% to $1.4 million in 2022, then spiked by 1,110.23% to $17.3 million in 2023, then crashed by 46.64% to $9.2 million in 2024, then fell by 26.98% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q3 2025, $9.4 million for Q2 2025, and $8.9 million during Q1 2025.